Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Abstract Text:

AIM: To study the effect of superselective ophthalmic artery fibrinolysis as a treatment for central retinal vein occlusion (CRVO). METHODS: Retrospective, university based single centre study. The charts of 26 eyes of 26 patients treated were reviewed. Among the 26 patients, there were nine cases of combined artery and vein occlusion, three cases of combined cilioretinal artery and CRVO, and 14 cases of classic CRVO. Complete preoperative and postoperative ophthalmological examination and fluorescein angiography were performed in all cases. The therapeutic procedure comprised the infusion of urokinase through a microcatheter into the ostium of the ophthalmic artery, via a femoral artery approach. The main outcome measure was the improvement in visual acuity 48 hours after the procedure. RESULTS: Six eyes of six patients exhibited significant improvement in visual acuity immediately after the fibrinolysis procedure. Among them, four had a initial funduscopic appearance suggestive of combined occlusion of the central retinal artery (CRAO) and vein. For these patients, the visual benefit was maintained in the long term. Intravitreal haemorrhage occurred in two patients. There were no extraocular complications linked to the procedure. CONCLUSIONS: Selective ophthalmic artery infusion of urokinase was followed by improvement in VA in six out of 26 cases of CRVO. Eyes with combined CRAO and CRVO with recent visual loss appeared to be the most responsive. This treatment did not prevent the occurrence of ischaemia in the failure cases. The efficacy of in situ fibrinolysis for treatment of CRVO needs to be further evaluated in a controlled study.

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Publishing Authors By Initials

For similar visual acuity research abstracts see: visual acuity research

PUBMED ID PMID:

MEDLINE DATE:

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The British journal of ophthalmology

VOLUME: 84

Page Numbers: 1387-91

Journal Abbreviation: Br J Ophthalmol

ISSN: 0007-1161

DAY: 28

MONTH: Dec

YEAR: 2000

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 421041

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Keywords Mesh Terms:

KEYWORDS: Visual Acuity

MESH TERMS: drug effects

Chemical & Substance for Abstract: Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Information

Substance Name: Urinary Plasminogen Activator

Registry Number: EC 3.4.21.73

Grant and Affiliation Information for Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.

AFFILIATION: Department of Ophthalmology, Hôpital Lariboisière, Université Paris 7, Paris, France. michel.paques@lrb.ap-hop-paris.fr

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Ophthalmol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion Related Publications

• Full-thickness macular hole in a patient with diabetic cystoid macular oedema treated by intravitreal triamcinolone injections.
• OPHDIAT((c)): Quality-assurance programme plan and performance of the network.
• Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema.
• Responding letter.
• Results of 203 total hip replacements using a smooth, cementless femoral component.
• Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.
• [Cellular absorption of diffusible and adsorbable substances; case of phenol and sulfanilamide.]
• [Effect of temperature on the statics and kinetics of cellular penetration of urea, thiourea and sulfanilamide.]
• [Locked volar plating for complex distal radius fractures: maintaining radial length]
• [Not Available.]
• [Sterilization apparatus.]